INTRODUCTION
============

Laparoscopic splenectomy (LS) is one of the many successful applications of minimally invasive surgical techniques. Since the first laparoscopic splenectomy performed in 1991 by Delaître, this approach has been adopted as the procedure of choice to treat benign splenic pathologies.^[@B1]^ However, data on laparoscopic splenic resection for malignant tumors is scarce because of the rarity of the occurrence of primary malignant tumors in the spleen. These tumors can be classified broadly as lymphoid and nonlymphoid. Non-Hodgkin\'s lymphoma is the most common primary lymphoid tumor, and angiosarcoma is the most common nonlymphoid malignant neoplasm. The remaining nonlymphoid tumors, such as hemangioendothelioma, malignant fibrous histiocytoma (MFH), fibrosarcoma, and leiomyosarcoma, are exceedingly rare and are only anecdotally reported. This report presents the first case of splenic malignant fibrous histiocytoma treated by LS reported in the international literature.

CASE REPORT
===========

A 76-year-old man presented to the Mayo Clinic with a 4-week history of left upper quadrant abdominal and flank pain. He had an intentional weight loss of 30 pounds over the past 18 months. A gastrointestinal review of systems was negative. He had no fever, sweats, or chills. His past medical history was significant for prostate cancer, recurrent kidney stones secondary to cystinuria, hypertension, coronary artery disease, and hyperlipidemia. His past surgical history included multiple stone extraction procedures, including bilateral open stone extractions. He underwent radical retropubic prostatectomy and pelvic lymphadenectomy in 1997.

On physical examination, he was well appearing, afebrile, and normotensive. His body mass index was 25kg/m^2^. His abdomen was soft, nondistended, slightly tender to palpation in the left upper quadrant; no masses or organomegaly were appreciated on deep palpation. Laboratory data showed a white blood cell count of 7,300/L, hemoglobin of 10.6g/dL, and platelets of 241,000/L. His creatinine was 1.4mg/dL.

An outside CT scan of the abdomen and pelvis with oral and intravenous contrast showed a 4.8 x 6.1 x 5-cm heterogenous splenic mass that was not present on a CT scan 10 months earlier **([Figure 1](#F1){ref-type="fig"})**. The mass had irregular borders and contained enhancing nodular and cystic components. It was reported as suspicious hemangioendothelioma, angiosarcoma, hemangiopericytoma, and other malignant processes, such as metastases or possibly infection. An incidental splenule was noted in the splenic hilum.

![CT scan of the abdomen showing a 4.8-cm AP x 6.1-cm width x 5-cm length nonhomogeneous mass in the spleen. This mass has an irregular outline and contains several enhancing nodules and cystic spaces.](jls0031026430001){#F1}

An ultrasound-guided biopsy of the splenic mass revealed a high-grade malignant neoplasm, unable to be further classified on cytology. A PET scan showed a centrally hypometabolic and peripherally hypermetabolic lesion in the spleen with a small central hematoma consistent with the biopsy done the day before. (Multiple foci of skeletal malignant type FDG uptake with associated subtle sclerosis were seen on L1, L3, left sacrum left iliac bone, left anterior superior iliac spine, and subtrochanteric left femur **([Figure 2](#F2){ref-type="fig"})**. There was circumferential uptake within a couple of loops of small bowel in the left lower quadrant that was considered most likely physiological. A contrast enhanced CT enterography confirmed noninvolvement of the bowel but showed splenic mass enlargement to 7.1 x 5.3cm. Upper endoscopy and colonoscopy identified a cecal tubulovillous adenoma without evidence of malignancy. A carcinoembryonic antigen level was 0.6ng/mL (normal), and PSA was \<0.10ng/mL.

![PET of the pelvis showing multiple foci of skeletal malignant-type FDG uptake, including left sacrum at the level of the S2 foramen and left iliac bone adjacent to the SI joint.](jls0031026430002){#F2}

Laparoscopic splenectomy, including the splenule was performed without any intraoperative complications. The patient had an uneventful postoperative course and was discharged on postoperative day 2. The final pathology confirmed an undifferentiated pleomorphic sarcoma, high grade (4 of 4). Postoperatively, a CT-guided biopsy of the left iliac bone lesion was negative for malignancy. The patient declined any treatment that would be based on the presumption of residual disease.

DISCUSSION
==========

In 1881, Theodor Billroth performed the first splenectomy for sarcoma in a 43-year-old woman with lymphosarcoma.^[@B2]^ She died 6 months later from recurrent disease. Since that time, splenectomy has remained the preferred treatment for splenic sarcomas. Malignant fibrous histiocytomas are rare and have been classified into 5 subtypes: pleomorphic, inflammatory, myxoid type, giant cell, and angiomatoid.^[@B3]^ They are most commonly found in the extremities. Intraabdominal locations account for approximately 20% of MFH.^[@B4]--[@B6]^

We have found only 15 cases of splenic MFHs reported in the international literature **([Table 1](#T1){ref-type="table"})**.^[@B7]--[@B18]^ Thirteen of the patients were treated with splenectomy, one patient had the tumor found on autopsy, and one patient did not receive any treatment. Patient ages ranged from 11 years to 82 years, with a mean age of 53. The reported survival ranged from 9 days to 18 months. Radiation was given to one of these patients after splenic resection, and chemotherapy was given to one patient. One patient was treated with combined chemotherapy and radiation. The splenic mass ranged from 375g to 1850g (mean, 1136). The tumor size ranged from 2.5cm to 21.5cm (mean, 12.9). To our knowledge, this is the first reported case of a splenic pleomorphic sarcoma treated by laparoscopic splenectomy.

###### 

Cases of Splenic Malignant Fibrous Histiocytoma Reported in the International Literature

  Study                     Case   Age   Gender   Spleen Size       Tumor Size (cm)   Subtype        Treatment                         Survival
  ------------------------- ------ ----- -------- ----------------- ----------------- -------------- --------------------------------- ------------------------------------
  Hashmi (2009)             1      76    M        375g              7.1 x 5.3         Pleomorphic    Laparoscopic splenectomy          To date
  Govoni (1982)7            2      51    F        1400g             21 x 25 x 10      Pleomorphic    Open splenectomy                  Alive at 7 months post op
  Wick (1982)8              3      48    M        1184g             8                 Inflammatory   Open splenectomy plus radiation   Alive with liver mets at 18 months
                            4      51    F        1400g                               Inflammatory   Open splenectomy                  Alive at 17 months
                            5      54    M        1235g                               Unknown        Open splenectomy                  Alive at 3 months
  Mallipudi (1998)9         6      73    W        15 × 10 × 8490g   10                Pleomorphic    Open splenectomy                  19 months
  Colovic (2001)10          7      45    F        14 × 12 × 7       11 × 10 × 7       Pleomorphic    Open splenectomy                  15 months
  Bonilla (1994)11          8      42    F                                            Unknown        Splenectomy, XRT, chemotx         4 months
  Katsuura (2006)^[@B3]^    9      82    M        13cm              2.5 × 3           Inflammatory   Open splenectomy                  Alive at 18 months
  Lieu (1993)1^[@B2]^       10     71    M        1870g             9.5               Pleomorphic    Open splenectomy                  9 days
  Ozaras (2003)1^[@B3]^     11     51    F                          12 × 11 × 10      Pleomorphic    Open splenectomy                  
  Sieber (1990)1^[@B4]^     12     41    M        28×17×12 1850g    21.5              Pleomorphic    Open splenectomy                  6 months
  Yu (1989)1^[@B5]^         13     11    F                          15 × 15 × 10      Inflammatory   Open splenectomy                  
  Jinno (1987)1^[@B6]^      14     53    M                                            Pleomorphic    Autopsy                           Autopsy
  Bruneton (1988)^[@B17]^   15     54    M                          20 cm                            Open (partial) splenectomy        3 months
  Yuan (2006)^[@B18]^       16                                                                       None                              

Laparoscopic splenectomy has become progressively accepted as an advantageous and safe approach for splenectomy^.^ It has been shown to have reduced morbidity and mortality rates compared with open splenec-tomy in many published series (morbidity 19% vs. 56%; mortality 2% vs. 18%).^[@B19]^ Most reports include patients with benign diseases and small spleens. LS for malignant disease can be a greater challenge, because of the size of the spleen and the general condition of the patient. Burch et al^[@B19]^ compared the outcomes of LS for benign versus malignant neoplasms. They showed that there was no statistically significant difference identified between those undergoing LS for benign versus malignant disease in terms of length of stay, complication rate, or mortality. Although there were significant differences between the 2 groups in terms of operative time, splenic weight, and the need for an accessory incision for spleen retrieval.

One criticism of the laparoscopic approach has been the lack of tactile feedback and perhaps an inability to identify accessory splenic tissue. The incidence of accessory spleen is approximately 15%.^[@B20]^ Failure to detect and ablate accessory splenic tissue may lead to treatment failure in case of malignancy. Studies show that the lack of the ability to palpate does not compromise the surgeon\'s ability to find and remove accessory splenic tissue when LS is compared to OS.^[@B21],[@B22]^

Patients with splenic sarcoma may be at risk for operative conversion to an open operation for bleeding. In fact, hemoperitoneum due to splenic rupture is seen in up to 13% to 30% of cases and is often the first manifestation of the disease.^[@B23]^

Maintaining the integrity of the capsule is advisable for both oncological and hemostatic reasons to minimize the chance of tumor dissemination or bleeding from the parenchyma. It is critical to avoid iatrogenic splenic rupture. Therefore, splenic size and surgeon experience are key determining factors when deciding on an open, a hand-assisted, or a total laparoscopic splenectomy.

CONCLUSION
==========

Primary malignancies of the spleen are rare and are primarily treated with splenectomy. This case report shows that laparoscopic splenectomy is a feasible operative choice for patients with sarcomas, allowing the advantages of laparoscopic surgery and a quicker healing process permitting earlier institution of adjuvant treatment if necessary. The large size and increased risk of bleeding will likely be the greatest challenges for surgeons performing laparoscopic splenectomy for splenic sarcomas.
